Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grail Encouraged By New Circulating Cell-free Genome Atlas Data

Executive Summary

A sub-analysis of the Circulating Cell-free Genome Atlas study show Grail's genome-sequencing technology may be able to detect early-stage lung cancer through DNA signals in the blood.

You may also be interested in...



Grail’s Liquid Biopsy Can Detect Numerous Deadly Cancer Types Early

Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.

VC Deals Analysis: Asia Investors Pour Money Into Grail And May's Other Big Deals

Asian investors' unrelenting pursuit of medtech ventures continued to crescendo in May. The participants in the largest round so far this year, the $300m series C by Illumina spin-out Grail, are all China-based funds.

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT122771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel